PTC Therapeutics, Inc. (PTCT)

31,00 -0,14 (-0,45 %) À partir de 12:34PM EDT. Marché ouvert.

PTC Therapeutics, Inc.

100 Corporate Court
South Plainfield, NJ 07080
United States
908 222 7000
https://www.ptcbio.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 988

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.	CEO & Director	1,24M	S.O.	1973
Dr. Stuart W. Peltz Ph.D.	Co-Founder, Senior Consultant & Member of Scientific Advisory Board	796,9k	S.O.	1960
Dr. Allan Steven Jacobson Ph.D.	Co-Founder, Chairman of Scientific Advisory Board & Independent Director	145k	S.O.	1946
Mr. Pierre Gravier M.S.	Chief Financial Officer	619,92k	S.O.	1986
Mr. Mark Elliott Boulding	Executive VP & Chief Legal Officer	761,94k	1,27M	1961
Mr. Eric Pauwels	Chief Business Officer	761,18k	S.O.	1961
Dr. Lee Golden M.D., Ph.D.	Executive VP & Chief Medical Officer	716,78k	S.O.	1968
Ms. Christine Utter	Senior VP, Chief Accounting Officer & Head of People Services	595,54k	995,57k	1978
Dr. Neil Almstead Ph.D.	Chief Technical Operations Officer	829,97k	S.O.	1967
Alex Kane	Investor Relations Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Gouvernance d’entreprise

L’ISS Governance QualityScore de PTC Therapeutics, Inc. en date du 1 mai 2024 est 5. Les scores principaux sont Audit : 7; Société : 2; Droits des actionnaires : 7; Compensation : 6.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.